The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors

Yusmiati Yusmiati, Dewi Muliaty


BACKGROUND: Cytochrome P450 (CYP) enzymes play important roles in human, including drug metabolism. CYP2 is the largest family of human CYP, with its sequence comprising almost one third of all CYP sequences, and responsible for the metabolism of approximately 2% of clinically administrated drugs. One of the most important enzymes in this family is the CYP2C19 enzyme. The CYP2C19 gene is polymorphic, and the variation is common especially in the Asian population.

CONTENT: CYP2C19 is responsible for the metabolism of various drugs, including proton pump inhibitors (PPIs) such as omeprazole and lansoprazole, psychotropic drugs including diazepam and imipramine, anticonvulsants such as phenobarbital and mephenytoin. and the recently most studied the anti-platelet drug, clopidogrel, and many others. Drugs metabolized predominantly by this enzyme like clopidogrel and PPIs might be much affected by the genotype status of CYP2C19. Clopidogrel is a pro-drug requiring a group of enzymes to convert to its active form, particularly the CYP2C19. PPIs are metabolized to its inactive metabolites mainly by CYP2C19 in the liver. Some PPIs are inhibitor of CYP2C19 enzymes, and interaction of PPIs and clopidogrel has been widely studied.

SUMMARY: The association of CYP2C19 genotypes with the plasma level of active clopidogrel and platelet reactivity in individual taking this drug is well-established. Although conflicting results still exist for the association of CYP2C19 genotypes to the clinical outcomes of clopidogrel therapy, this effect seems to be consistent in patients receiving clopidogrel for coronary stents. Due to the interaction of certain PPIs and clopidogrel, the use of PPIs other than omeprazole is recommended, especially for patients taking dual anti platelet therapy of clopidogrel and aspirin.

KEYWORDS: pharmacogenetics, CYP2C19, proton pump inhibitors, clopidogrel

Full Text:



Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Current Drug Metabolism. 2002; 3: 561-97, CrossRef.

Foti RS, Wahlstrom JL. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008; 36: 523-8, CrossRef.

Perry CG, Shuldiner AR. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? J Hum Genet. 2013; 58: 339-45, CrossRef.

[n.a]. Plavix prescribing information [updated 2013 Des; cited 2014 Mar 10]. Available from:

Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002; 360: 1155-62, CrossRef.

Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007; 76: 391-6, PMID.

Nelson DR. The cytochrome P450 homepage. Human Genomics. 2009; 4: 59-65, PMID.

Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, et al. The P450 gene superfamily: recommended nomenclature. DNA. 1987; 6: 1-11, CrossRef.

Nelson DR. Cytochrome P450 nomenclature. In: Phillips IR, Shephard EA, editors. Methods in Molecular Biology, Vol.107: cytochrome P450 protocols. Totowa NJ: Humana Press Inc; 1998. p.15-24, CrossRef.

Buck ML. The cytochrome P450 enzyme system and its effect on drug metabolism. Pediatr Pharmacotherapy. 1997; 3, article.

Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004; 25: 193-200, CrossRef.

Alain LWP, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J ClinPharmacol. 2010; 69: 222-230, CrossRef.

Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Brit J ClinPharmacol. 2001; 52: 349-55, CrossRef.

Sim SC. Human Cytochrome P450 (CYP) Allele Nomenclature Committee: CYP2C19 allele nomenclature for cytochrome P450 enzymes [cited 2014 Mar 1]. Available at: http: //

De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269: 15419-22, PMID.

De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese. Mol Pharmacol. 1994; 46: 594-8, PMID.

Ozdil B, Akkiz H, Bayram S, Bekar A, Akgoll E, Sandikci M. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication. Turk J Gastroenterol. 2010; 21: 23-28, PMID.

Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. Circulation. 2010; 122: 537-57, CrossRef.

Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 Allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential Effect. Drug Metab Dispos. 2010; 38: 894-97, CrossRef.

Sim SC , Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. Common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors andantidepressants. Clin Pharmacol Ther. 2006; 79: 103-13, CrossRef.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010; 121: 512-18, CrossRef.

Lyon E, Foster JG, Palomaki GE, Pratt VM, Reynolds K, Sabato MF,, Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet Med. 2012; 14: 990-1000, CrossRef.

Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical pharmacogenetic simplementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90: 625-29, CrossRef.

Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in a Tamilian population. J Clin Pharmacol. 2003; 56: 331-33, CrossRef.

Strom CM, Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med. 2012; 14: 95-100, CrossRef.

Yusmiati, Mulatsih R, Fattah M, Santoso A, Sukmawan R, Soedarmo. Assessment of CYP2C19 *2 and *3 genetic polymorphisms frequencies in Indonesian population using PCR-RFLP method. Bali: 13th Asian Pacific Federation of Clinical Biochemistry Congress; 2013.

Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinctcarboxylesterases, and clopidogrel is transesterificated in the presence of ethylalcohol. J Pharmacol Exp Ther. 2006; 319: 1467-76, CrossRef.

Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010; 20: 463-5, CrossRef.

Kazui M, Nichiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug MetabDispos.2010; 38: 92-99, CrossRef.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Eng J Med. 2009; 360: 354-62, CrossRef.

Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108: 2244-7, CrossRef.

Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008; 84: 236-42, CrossRef.

Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome p450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302: 849-57, CrossRef.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost. 2011; 105: S55-9, CrossRef.

Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park YW, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Cardiovasc Interv. 2011; 4: 585-94, CrossRef.

Simon T, Verstuyft C, Mary-Krause M, Quteinech L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75, CrossRef.

Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373: 309-17, CrossRef.

Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009; 30: 916-22, CrossRef.

Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009; 103: 806-11, CrossRef.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G_A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am CollCardiol. 2008; 51: 1925-34, CrossRef.

Mega JL, Simon T, Collect JP, Anderson JL, Antman EM, Bilden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrelpredominantly for PCI: a meta-analysis. JAMA. 2010;304: 1821-30, CrossRef.

Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011; 11: 199-206, CrossRef.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, Berg JMT, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and metaanalysis. BMJ. 2011; 343: d4588, CrossRef.

Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA. 2011; 306: 2704-14, CrossRef.

Shuldiner AR, Vesely MR, Fisch A. CYP2C19 genotype and cardiovascular events. JAMA. 2012; 307: 1482-85, CrossRef.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 1010; 376: 1312-9, CrossRef.

Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376: 1320-8, CrossRef.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler ThrombVasc Biol. 2006; 26: 1895-900, CrossRef.

Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity aftertreatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008; 101: 1088-93, CrossRef.

Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, et al. Paraoxonase-1 is a major determinant of clopidogrelefficacy. Nat Med. 2011; 17: 110-6, CrossRef.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Euro Heart J. 2011: 32: 1605-13, CrossRef.

Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al. CYP2C19 but not PON1 genetic variants influence clopidogrelpharmacokinetics, pharmacodynamics, and clinical efficacy in post–myocardial infarction patients. Circ Cardiovasc Interv. 2011; 4: 422-8, CrossRef.

Mega JL, Hocholzer W, Frelinger AL, Kluk MJ, Angiolillo D, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivityin patients with stable cardiovascular disease. JAMA. 2011; 306: 2221-8, CrossRef.

Varenhorst C, James S, Erlinge D, Brandt JT, Braun O, Man M, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamics responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Euro Heart J. 2009; 30: 1744-52, CrossRef.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Thromb Haemost. 2007; 5: 2429-36, CrossRef.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel. The RESET GENE trial. Circ Cardiovasc Interv. 2012; 5: 698-704, CrossRef.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-15, CrossRef.

Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelorversus clopidogrel: The ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010; 3: 556-66, CrossRef.

Anderson CK, Biffi A, Greenberg SM. Personalized approaches to clopidogrel therapy: are we there yet? Stroke. 2010; 4: 2997-3002, CrossRef.

Reese ES, Mullins CD, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy. 2012; 32: 323-32, CrossRef.

Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013; 17: 165-84, CrossRef.

Shin JM, Kim NY. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013; 19: 25-35, CrossRef.

Hunfeld NG, Mathot RA, Touw DJ, van schaik RH, Mulder PG, Franck PF, et al. Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008; 65: 752-60, CrossRef.

TangHL, Li Y, Hu YF, Xie HG, Zha SD. Effects of CYP2C19 loss-off-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: ameta-analysis of randomized clinical trials. Plos One. 2013; 8: e62162, CrossRef.

Aoyama N, Tanigawara Y, Kita T, Sakai T, Shirakawa K, Shirasaka D, et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol. 1999; 34 (Suppl 11): 80-3, PMID.

Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res. 2008; 127: 521-30, PMID.

Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007; 8: 1199-210, CrossRef.

Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004; 76: 201-9, CrossRef.

Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006; 101: 1467-75, CrossRef.

Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a metaanalysis. Helicobacter. 2008; 13: 532-41, CrossRef.

McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012; 36: 414-25, CrossRef.

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124: e574-651, CrossRef.

Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos.1997; 25: 853-62, PMID.

Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011; 39: 2020-33, CrossRef.

Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R, et al. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug Metab Dispos. 2012; 40: 187-97, CrossRef.

Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol .2010; 70: 383-92, CrossRef.

Kenngott S, Olze R, Kollmer M, Bottheim H, Laner A, Holinski-Feder E, et al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur J Med Res. 2010; 15: 220-24, CrossRef.

Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole C Lopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51: 256-60, CrossRef.

Lin CF, Shen LJ, Wu FLL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012; 74: 824-34, CrossRef.

Ho PQ, Maddox TM, Wang Li, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301: 937-44, CrossRef.

Juurlink DN, Gomes T, Ko DT. Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180: 713-8, CrossRef.

Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study. Ann Intern Med. 2010; 152: 337-45, CrossRef.

Rassen JA, Choudhry NT, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009; 120: 2322-29, CrossRef.

Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363: 1909-17, CrossRef.

Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction results from the French registry of acute ST-elevation and non–ST-elevation myocardial infarction (FAST-MI) registry. Circulation. 2011; 123: 474-82, CrossRef.

Banerjee S, Weideman RA, Weideman MW, Little BB, Kelly KC, Gunter JT, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol. 2011; 107: 871-8, CrossRef.

Harjai KJ, Shenoy C, Orshaw P, Usmani S, Boura J, Mehta RH. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the guthrie health off-label stent (GHOST) investigators. Circ Cardiovasc Interv. 2011; 4: 162-70, CrossRef.

Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors - Where do we stand in 2012? World J Gastroenterol. 2012; 18: 2161-71, CrossRef.

Fernando H, Dart AM, Peter K, Shaw JA. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost. 2011; 105: 933-44, CrossRef.

Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors oncardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010; 31: 810-23, CrossRef.

Lima JPA, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Medicine. 2010; 8: 81, CrossRef.

Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemos. 2010; 8: 2624-41, CrossRef.


Copyright (c) 2014 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute